[{"id":"c31fe31a-3823-4e8c-81cc-892c70bccfed","acronym":"","url":"https://clinicaltrials.gov/study/NCT07206849","created_at":"2025-10-11T01:31:02.610Z","updated_at":"2025-10-11T01:31:02.610Z","phase":"Phase 2","brief_title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","source_id_and_acronym":"NCT07206849","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2025-10-03"},{"id":"59fe4335-1fcc-4358-b0b0-f40604168b4d","acronym":"HERKULES-3","url":"https://clinicaltrials.gov/study/NCT05039177","created_at":"2021-09-09T13:53:09.950Z","updated_at":"2025-02-25T15:19:15.517Z","phase":"Phase 1/2","brief_title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","source_id_and_acronym":"NCT05039177 - HERKULES-3","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"b6564bde-b8d0-4ec2-957a-4f9dc888300c","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT01362803","created_at":"2021-01-18T05:34:38.658Z","updated_at":"2025-02-25T15:25:09.588Z","phase":"Phase 1/2","brief_title":"AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors","source_id_and_acronym":"NCT01362803 - SPRINT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 09/21/2011","start_date":" 09/21/2011","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2032","study_completion_date":" 01/01/2032","last_update_posted":"2025-02-11"},{"id":"f8aa54b6-cac6-4d9e-ad7f-1c17ff88bf8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04590235","created_at":"2021-01-18T21:53:34.262Z","updated_at":"2025-02-25T16:10:42.940Z","phase":"Phase 1","brief_title":"A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","source_id_and_acronym":"NCT04590235","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 08/16/2022","primary_completion_date":" 08/16/2022","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-11-19"},{"id":"f30ecff2-7653-43cc-b571-141733c1cb0d","acronym":"TWT-101","url":"https://clinicaltrials.gov/study/NCT04521413","created_at":"2021-01-18T21:39:25.557Z","updated_at":"2024-07-02T16:35:10.432Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","source_id_and_acronym":"NCT04521413 - TWT-101","lead_sponsor":"Treadwell Therapeutics, Inc","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CFI-402411"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-10"},{"id":"a03225ff-24b0-4deb-bd39-a4f4a7489157","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221320","created_at":"2022-02-05T18:29:02.167Z","updated_at":"2024-07-02T16:35:19.608Z","phase":"Phase 2","brief_title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","source_id_and_acronym":"NCT05221320","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3","pipe":" | ","alterations":" MSI-H/dMMR","tags":["KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 12/06/2024","primary_completion_date":" 12/06/2024","study_txt":" Completion: 03/19/2025","study_completion_date":" 03/19/2025","last_update_posted":"2024-02-13"},{"id":"dde5d7d2-1dad-4eff-ab54-2b67e2cc553a","acronym":"HERKULES-2","url":"https://clinicaltrials.gov/study/NCT04959981","created_at":"2021-12-13T15:11:31.264Z","updated_at":"2024-07-02T16:35:42.103Z","phase":"Phase 1b","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC","source_id_and_acronym":"NCT04959981 - HERKULES-2","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/02/2021","start_date":" 09/02/2021","primary_txt":" Primary completion: 04/27/2023","primary_completion_date":" 04/27/2023","study_txt":" Completion: 04/27/2023","study_completion_date":" 04/27/2023","last_update_posted":"2023-07-25"},{"id":"8c9cfa8a-68b7-4249-9e5a-7442d470cca3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04495127","created_at":"2021-01-18T21:35:26.897Z","updated_at":"2024-07-02T16:35:49.602Z","phase":"Phase 1","brief_title":"Selumetinib Paediatric NF1 Japan Study","source_id_and_acronym":"NCT04495127","lead_sponsor":"AstraZeneca","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 06/16/2021","primary_completion_date":" 06/16/2021","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2023-04-26"},{"id":"330ac409-c653-4ffe-b5ad-e37d750b01db","acronym":"HERKULES-4","url":"https://clinicaltrials.gov/study/NCT05279859","created_at":"2022-03-15T18:52:50.830Z","updated_at":"2024-07-02T16:36:08.894Z","phase":"Phase 1b/2","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05279859 - HERKULES-4","lead_sponsor":"Erasca, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • ERAS-007 • ERAS-601"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-06-15"},{"id":"ea39bf9b-3a98-46eb-8bfc-59230c1a4e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395780","created_at":"2022-05-27T11:56:31.465Z","updated_at":"2024-07-02T16:36:09.466Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05395780","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-06-02"},{"id":"c7c7b388-a345-4c9d-9046-42dc16d8c6a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05369286","created_at":"2022-05-11T16:55:50.518Z","updated_at":"2024-07-02T16:36:10.590Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05369286","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FGFR1OP2","pipe":" | ","alterations":" FGFR1 expression","tags":["FGFR1OP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2022-05-11"},{"id":"b185f5af-b20b-432d-b8f0-d2a61b2a09b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03412292","created_at":"2021-01-18T16:50:05.305Z","updated_at":"2024-07-02T16:36:18.334Z","phase":"Phase 1","brief_title":"MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)","source_id_and_acronym":"NCT03412292","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" FLT3 • FGFR","pipe":" | ","alterations":" FLT3 wild-type","tags":["FLT3 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Max-40279"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-01-19"},{"id":"910f01e8-e129-4f75-9739-81c5fb413c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05130021","created_at":"2021-11-22T14:53:41.790Z","updated_at":"2024-07-02T16:36:19.855Z","phase":"Phase 2","brief_title":"A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT05130021","lead_sponsor":"Maxinovel Pty., Ltd.","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • RAS wild-type","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Max-40279"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 05/30/2022","primary_completion_date":" 05/30/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2021-12-06"}]